Telix Pharmaceuticals Limited
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Telix Pharmaceuticals Limited's past years’ income statements indicate that its last revenue has increased compared to the previous period by 10512% to $496,659,000. The net income raised on $5,211,000 and profit margin reached 1%. Total operating expenses were $308,502,000.

Profit Margin

Telix Pharmaceuticals Limited (NASDAQ:TLX): Profit margin
2014 28.33M 5.43M 19.18%
2015 32.31M -2.39M -7.42%
2017 31.76M -5.59M -17.62%
2020 4.68M -44.88M -959.12%
2023 496.65M 5.21M 1.05%

TLX Income Statement (2014 – 2023)

2023 2020 2017 2015 2014
Revenue
Revenue
496.65M4.68M31.76M32.31M28.33M
Cost of revenue
188.15M2.02M53.83M24.86M22.62M
Gross profit
308.50M2.65M-22.06M7.45M5.71M
Operating exp.
Research and development
128.84M23.08M000
Selling and marketing
54.86M1.20M000
Total operating expenses
308.50M52.44M-8.54M10.40M10.66M
Operating income
17.02M-46.76M-2.78M-1.94M-5.07M
Other income (expenses), net
-13.94M1.85M-1.89M-419.64K10.53M
Income before tax
3.08M-47.93M-4.67M-2.36M5.46M
Income tax expense
-2.12M-3.04M920.20K31.54K33.73K
Net income
5.21M-44.88M-5.59M-2.39M5.43M
Earnings per share
Basic EPS
00-0.49-0.200.47
Diluted EPS
00-3.26-1.433.97
Data sourceData sourceData source